Stock 4599 STEMRIM
Add to a list
To use this feature you must be a member
Log inSign up

StemRIM Stock

Equities

4599

JP3399690001

Pharmaceuticals

Delayed Japan Exchange
Other stock markets
 08:21:11 2024-04-24 pm EDT 		5-day change 1st Jan Change
445 JPY -0.22% Intraday chart for StemRIM +1.14% -23.01%
Mar. 13 StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy CI
Jan. 31 StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders CI

Financials

Sales 2024 * 1B 6.44M Sales 2025 * 540M 3.48M Capitalization 27.43B 177M
Net income 2024 * -1.29B -8.33M Net income 2025 * -1.68B -10.81M EV / Sales 2024 * 27.4 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 50.8 x
P/E ratio 2024 *
-21 x
P/E ratio 2025 *
-16.3 x
Employees 45
Yield 2024 *
-
Yield 2025 *
-
Free-Float 41.55%
More Fundamentals * Assessed data

Chart StemRIM

Dynamic Chart

Latest news about StemRIM

StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy CI
StemRIM Inc. Announces Patent Registration for the Use of the HMGB1 Fragment Peptide, as an Additional Therapeutic Indication of Cartilage Disorders CI
StemRIM Allocates 300 Stock Options to R&D Partner MT
StemRIM to Issue Stock Acquisition Rights MT
StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation MT
StemRIM Enters into Contract for Implementation of Phase 2 Investigator-Initiated Clinical Trial Targeting Ischemic Cardiomyopathy Using Redasemtide, in Collaboration with Osaka University Hospital and Shionogi & Co CI
StemRIM Issues 433,000 Shares as Restricted Stock Compensation MT
StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration MT
StemRIM Discloses Issuance Details of Stock Options to Directors MT
Stemrim Inc. Announces Patent Registration (Us) for the Use of the Hmgb1 Fragment Peptide, Redasemtide CI
StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction CI
StemRIM Inc. Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke CI
StemRIM Inc. Announces Commencement of Global Late Phase 2 Clinical Trial for Redasemtide in Patients with Acute Ischemic Stroke in the Europe and China CI
StemRIM Inc. Announces Patent Registration for the Use of the Hmgb1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction CI
StemRIM Provides Earnings Guidance for the Year Ending July 31, 2023 CI
More news

Press releases StemRIM

Shionogi & Co., Ltd. - Orphan Drug Designation for Redasemtide for Dystrophic Epidermolysis Bullosa AQ
SHIONOGI Announces Positive Results from a Phase 2 Clinical Trial of the Regeneration Inducing Medicine S-005151 in Patients with Acute Ischemic Stroke AQ
More press releases

Quotes and Performance

1 day-0.22%
1 week+1.14%
Current month-9.18%
1 month-11.35%
3 months-17.29%
6 months-31.33%
Current year-23.01%
More quotes

Highs and lows

1 week
419.00
Extreme 419
453.00
1 month
419.00
Extreme 419
524.00
Current year
419.00
Extreme 419
620.00
1 year
419.00
Extreme 419
1 320.00
3 years
419.00
Extreme 419
1 518.00
5 years
278.00
Extreme 278
1 518.00
10 years
278.00
Extreme 278
1 518.00
More quotes

Managers and Directors - StemRIM

Managers TitleAgeSince
Masatsune Okajima CEO
 Chief Executive Officer 56 19-02-28
Kensuke Tomita CHM
 Chairman 75 13-06-30
Tomoyuki Hoshino ADM
 Chief Administrative Officer - -
Members of the board TitleAgeSince
Masatsune Okajima CEO
 Chief Executive Officer 56 19-02-28
Kensuke Tomita CHM
 Chairman 75 13-06-30
Koichi Yokota CTO
 Chief Tech/Sci/R&D Officer 66 13-08-31
More insiders

Quotes

Date Price Change Volume
24-04-24 445 -0.22% 3 700
24-04-24 446 +0.68% 84,900
24-04-23 443 -1.12% 120,600
24-04-22 448 +5.41% 128,800
24-04-19 425 -3.19% 152,800

Delayed Quote Japan Exchange, April 24, 2024 at 08:21 pm EDT

More quotes

Company Profile

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Sector
Pharmaceuticals
Calendar
2024-06-12 - Q3 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for StemRIM

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
STEMRIM Stock StemRIM
-23.01% 176M
CSL LIMITED Stock CSL Limited
-2.86% 87.37B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 41.01B
BIOGEN INC. Stock Biogen Inc.
-21.94% 28.08B
UCB Stock UCB
+53.11% 24.72B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.47B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.69B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.56B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-0.22% 8.44B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4599 Stock